Guidance

Hexavalent vaccine DTaP/IPV/Hib/HepB: PGD template

PGD template for administering hexavalent vaccine following national recommendations and the routine childhood immunisation programme.

• From: UK Health Security Agency
• Published: 31 July 2017
• Last updated: 29 July 2022 — See all updates

Applies to England

Documents

Hexavalent vaccine, DTaP/IPV/Hib/HepB: Patient Group Direction (PGD) template

Ref: UKHSA gateway number: GOV-12873

MS Word Document, 152 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of hexavalent vaccine, DTaP/IPV/Hib/HepB, in accordance with national recommendations and the routine childhood immunisation programme.

DTaP/IPV/Hib/HepB PGD v04.00 is valid from 25 July 2022 to 24 July 2024.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.

Published 31 July 2017
Last updated 29 July 2022 + show all updates

1. 29 July 2022

   Added v04.00 – see page 2 for change history.

2. 9 August 2021

   Added updated PGD.

3. 2 August 2019

   Replaced PDG template with version v02.00, valid from 1 September 2019 to 31 August 2021.

4. 31 July 2017

   First published.